Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Paysign, Inc. (PAYS) SEC Filings & Earnings Calls

EquiReason read 9 Paysign, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Paysign reported strong Q2 2026 results with revenue up 48% YoY, net income up 387% YoY, and operating cash flow turning positive..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PAYSPaysign, Inc.Follow PAYS — free
Software - Infrastructure · Technology
—
Price chart with a free account
Market cap
842.4M
P/E TTM
55.3
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

6 Aug 202610-QPaysign reported strong Q2 2026 results with revenue up 48% YoY, net income up 387% YoY, and operating cash flow turning positive.earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q2-2026$28M+48% y/y
Plasma industry revenue · Plasma · Q2-2026$13M+21% y/y
Pharma industry revenue · Pharma · Q2-2026$15M+89% y/y
Gross profit · Q2-2026$18M+52% y/y
Net income · Q2-2026$7M+387% y/y
Basic EPS · Q2-2026$0.12+300% y/y
Cash and restricted cash · 2026-06-30$176M+55% y/y
Operating cash flow · H1-2026$20M
Gross margin · Q2-202663.3%

Risks flagged

Customer concentration

“One pharma patient affordability customer individually represented 36% of our accounts receivable balance.” · word for word

Bank concentration risk

“The Company maintains its cash and cash equivalents and restricted cash in various bank accounts primarily with one financial institution in the United States.” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02Paysign reported record Q2 2026 revenue of $28.3M (+48% YoY), GAAP net income $6.76M, and raised full-year outlook. Pharma revenue surged 89% and plasma revenue grew 21%.earningsopen

Figures in the filing · each found in the filing text

Total Revenues · Q2-2026$28M+48% y/y
Pharma Revenue · Pharma · Q2-2026$15M+89% y/y
Plasma Revenue · Plasma · Q2-2026$13M+21% y/y
Gross Profit Margin · Q2-202663.3%
Operating Margin · Q2-202624.8%
GAAP Net Income · Q2-2026$7M+386% y/y
Adjusted EBITDA · Q2-2026$10M+113% y/y
Diluted Adjusted EBITDA per share · Q2-2026$0.16+100% y/y
GAAP Diluted EPS · Q2-2026$0.11+450% y/y
Active Pharma Programs · Pharma · 2026-06-30148

Guidance

FY26 revenue $114.0M to $117.0M; Adjusted EBITDA $35.0M to $38.0M

Raised full-year outlook citing strong Q2 results and momentum across pharma and plasma businesses.

Risks flagged

Plasma center count declining, though per-center revenue improving

“total net plasma center count decreased by 46 during the past 12 months, exiting the quarter with 561 centers.” · word for word
Read the original on SEC EDGAR ↗
13 May 202610-QTotal revenues $28M (+51% y/y); Net income $5M (+110% y/y); Gross profit $18M (+56% y/y)open

Figures in the filing · each found in the filing text

Total revenues · Q1-2026$28M+51% y/y
Net income · Q1-2026$5M+110% y/y
Gross profit · Q1-2026$18M+56% y/y
Operating cash flow · Q1-2026$19M
Read the original on SEC EDGAR ↗
12 May 20268-K · 2.02Revenue $28M (+51% y/y); Pharma revenue $16M (+82% y/y); Plasma revenue $12M (+25% y/y)earningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$28M+51% y/y
Pharma revenue · Pharma · Q1-2026$16M+82% y/y
Plasma revenue · Plasma · Q1-2026$12M+25% y/y
Net income · Q1-2026$5M+110% y/y
Adjusted EBITDA · Q1-2026$11M+113% y/y
Gross margin · Q1-202665.0%
Operating margin · Q1-202623.8%
Unrestricted cash · Q1-2026$21M
Active patient affordability programs · Pharma · Q1-2026135
Net plasma center count · Plasma · Q1-2026573

Risks flagged

Plasma center attrition: 20 centers sold to competitors, 2 closed due to underperformance

“We exited the quarter with 573 centers versus 595 centers at the end of 2025 as 20 centers were sold to companies who use a competing provider and two underperforming centers were closed.” · word for word

Stock compensation expense increased 91% to $1.28M, potentially diluting shareholders

“stock compensation expense increased 91.0% to $1.28 million” · word for word
Read the original on SEC EDGAR ↗
26 Mar 2026DEF 14AAnnual proxy statement filed; no material governance or compensation changes.open

Figures in the filing · each found in the filing text

Net Income · FY2025$8M+98% y/y
Total Shareholder Return (cumulative $100 investment) · FY2025$171.00+58% y/y
Read the original on SEC EDGAR ↗
25 Mar 202610-KTotal revenues $82M (+40% y/y); Gross profit $49M (+51% y/y); Gross margin 59.4; Guidance: No specific numerical guidance provided; management plans to continue investing in growth.open

Figures in the filing · each found in the filing text

Total revenues · FY2025$82M+41% y/y
Gross profit · FY2025$49M+51% y/y
Gross margin · FY202559.4%
Net income · FY2025$8M+98% y/y
Adjusted EBITDA · FY2025$20M+107% y/y
Adjusted EBITDA margin · FY202524.3%
Operating cash flow · FY2025$52M+129% y/y
Gross dollar volume loaded on cards · FY2025$1.94B+9% y/y
Revenue conversion rate · FY20254.2%
Card programs · FY2025670

Guidance

No specific numerical guidance provided; management plans to continue investing in growth.

Management plans to continue investing in technology, sales, marketing, cybersecurity, fraud, customer service, and regulatory compliance in 2026. Believes internally generated funds will support existing business and expansion into new verticals.

Risks flagged

Plasma donation volume decline

“decline in plasma donations and dollars loaded to cards as plasma inventory levels were elevated throughout much of 2025, which has reduced our average monthly revenue per center” · word for word

Regulatory compliance cost

“We operate in a highly regulated environment and are subject to extensive regulation, supervision and examination.” · word for word

Customer concentration

“We have no major customers and are not reliant on any individual card program.” · word for word
Read the original on SEC EDGAR ↗
24 Mar 20268-K · 2.02Total revenue $82M (+40% y/y); Net income $8M (+98% y/y); Adjusted EBITDA $20M (+107% y/y)earningsopen

Figures in the filing · each found in the filing text

Total revenue · FY2025$82M+41% y/y
Net income · FY2025$8M+98% y/y
Adjusted EBITDA · FY2025$20M+107% y/y
Pharma revenue · Pharma · FY2025$34M+168% y/y
Plasma revenue · Plasma · FY2025$46M+4% y/y
Net plasma center count · Plasma · FY2025595
Active patient affordability programs · Pharma · FY2025131
Gross margin · FY202559.4%
Operating margin · FY20259.0%
Unrestricted cash · FY2025$21M

Risks flagged

Plasma revenue per center declining

“average revenue per plasma center per month of $7,067, down from $7,510” · word for word

Elevated effective tax rate

“effective tax rate of 24.7% versus 7.8%” · word for word
Read the original on SEC EDGAR ↗
13 Nov 202510-QPaysign reported strong Q3 2025 results with total revenue +41.6% YoY, driven by pharma patient affordability programs (+141.9% YoY), and significant margin expansion.earningsopen

Figures in the filing · each found in the filing text

Gross Dollar Volume Loaded on Cards · Q3-2025$552M+21% y/y
Revenue Conversion Rate · Q3-20253.9%
Gross Profit Conversion Rate · Q3-20252.2%
Net Income Conversion Rate · Q3-20250.4%
Adjusted EBITDA · Q3-2025$5M+78% y/y
Adjusted EBITDA Margin · Q3-202523.3%
Revenue · Q3-2025$22M+42% y/y
Gross Margin · Q3-202556.3%
Net Income · Q3-2025$2M+54% y/y
Net Margin · Q3-202510.3%

Risks flagged

Plasma Revenue Per Center Decline

“The increase in plasma revenue was primarily due to the addition of 117 net plasma centers during the past 12 months offset by a decline in plasma donations and dollars loaded to cards as plasma inventory levels have normalized, which has reduced our average monthly revenue per center as compared to the same period in the prior year.” · word for word

Operating Cash Flow Volatility

“The changes in accounts receivable, accounts payable, and customer card funding, a net decrease of $12,667,611, are primarily related to the growth in our pharma patient affordability business and timing of pass-through payments as we are invoiced by third-party service providers at the end of the period and are due monies from our pharma patient affordabili” · word for word
Read the original on SEC EDGAR ↗
12 Nov 20258-K · 2.02Total revenues $22M (+42% y/y); Net income $2M (+54% y/y); Adjusted EBITDA $5M (+78% y/y); Guidance: Expect to add 20-30 pharma programs before year endearningsopen

Figures in the filing · each found in the filing text

Total revenues · consolidated · Q3-2025$22M+42% y/y
Net income · consolidated · Q3-2025$2M+54% y/y
Adjusted EBITDA · consolidated · Q3-2025$5M+78% y/y
Diluted EPS · consolidated · Q3-2025$0.04+33% y/y
Plasma revenue · plasma · Q3-2025$13M+12% y/y
Pharma patient affordability revenue · pharma · Q3-2025$8M+142% y/y
Plasma centers · plasma · Q3-2025595+25% y/y
Active pharma programs · pharma · Q3-2025105+59% y/y
Average monthly revenue per plasma center · plasma · Q3-2025$7122.00-11% y/y
Average quarterly revenue per pharma program · pharma · Q3-2025$75434.00+52% y/y

Guidance

Expect to add 20-30 pharma programs before year end

Record revenue and profitability; pharma segment accelerating; new contact center expansion; positive outlook.

Risks flagged

Decline in average monthly revenue per plasma center due to normalized plasma inventory levels.

“average monthly revenue per plasma center decreased to $7,122 compared to $7,991 for the same period last year” · word for word

Wage inflation and tight labor market increasing customer care costs.

“wage inflation pressures, a tight labor market, and increased benefit costs” · word for word

Plasma center closures: 12 centers closed in Q3 due to underperformance.

“a reduction of 12 centers from the prior quarter, due to planned center closures of underperforming centers” · word for word
Read the original on SEC EDGAR ↗

Paysign, Inc. — questions

What did Paysign, Inc. file recently?
9 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Paysign reported strong Q2 2026 results with revenue up 48% YoY, net income up 387% YoY, and operating cash flow turning positive.

Every figure on this page comes from Paysign, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.